What is it about?
Review at the time of FDA approval of Etelcalcetide is approved for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis
Featured Image
Why is it important?
Formulary evaluation of the evidence available at the time of FDA approval
Perspectives
New treatment for secondary hyperparathyroidism in adults with CKD receiving hemodialysis
Danial Baker
Washington State University
Read the Original
This page is a summary of: Etelcalcetide, Hospital Pharmacy, September 2017, SAGE Publications,
DOI: 10.1177/0018578717733478.
You can read the full text:
Contributors
The following have contributed to this page
